Residency · Residency · Psychiatry

Augmentation Strategies in Treatment-Resistant Depression

Defining Treatment-Resistant Depression (TRD)

Standard Definition

Failure to achieve adequate response after at least two adequate trials of antidepressants from different pharmacologic classes. An "adequate trial" = therapeutic dose for a minimum of 4-6 weeks with documented adherence. Partial response: some improvement (e.g., 25-49% reduction in HAM-D score) but persistent residual symptoms. Non-response: less than 25% symptom reduction.

Pseudo-Resistance: Rule Out First

Inadequate dose or duration of previous trials. Non-adherence (up to 50% of patients within 6 months) Unrecognized comorbid conditions: substance use, medical illness (hypothyroidism, anemia, sleep apnea), personality disorders. Incorrect diagnosis: bipolar depression misdiagnosed as unipolar, PTSD, ADHD, or adjustment disorder. Pharmacokinetic factors: rapid metabolizer status (CYP2D6, CYP2C19), drug-drug interactions.

Staging Models

Thase and Rush staging model: Stage I (1 adequate trial failure) through Stage V (failure of ECT) Massachusetts General Hospital (MGH) staging method: scores based on number, intensity, and optimization of failed trials. European Staging Model and Maudsley Staging Method also used in research.

The STAR*D Trial Framework

Study Design

Sequenced Treatment Alternatives to Relieve Depression (STAR*D): largest real-world antidepressant effectiveness trial (n = 4,041) Funded by NIMH; enrolled outpatients with nonpsychotic MDD from primary care and psychiatric settings. Level 1: citalopram monotherapy. Level 2: switch (sertraline, venlafaxine, bupropion, or cognitive therapy) or augment (bupropion or buspirone) Level 3: switch (nortriptyline or mirtazapine) or augment (lithium or thyroid hormone) Level 4: switch to tranylcypromine (MAOI) or mirtazapine + venlafaxine combination.

Key Findings

Level 1 remission rate: ~33%. Cumulative remission after all levels: ~67%. Each successive level yielded diminishing remission rates and increasing dropout. Switching vs. augmenting at Level 2: similar remission rates (~25%) Bupropion augmentation and buspirone augmentation had similar efficacy but bupropion was better tolerated. Lithium and T3 augmentation at Level 3 showed similar efficacy (~15-20% remission), but lithium had more side effects and dropouts. Relapse rates increased with each successive treatment step.

Clinical Implications

Measurement-based care with validated scales (PHQ-9, QIDS) is essential for tracking response. Patients who do not remit with first-line treatment need systematic, sequential management. Both switching and augmenting are reasonable strategies; clinical context guides the decision. The trial underscores that TRD is common and that persistence through sequential steps matters.

Augmentation Strategies

Lithium Augmentation

One of the most evidence-based augmentation strategies; studied since the 1980s. Effective at lower doses than those used for bipolar disorder (target serum level 0.4-0.8 mEq/L) Proposed mechanism: enhances serotonergic neurotransmission, inhibits GSK-3beta, neuroprotective via BDNF. Response typically seen within 2-4 weeks. Requires monitoring: serum lithium levels, renal function (creatinine, eGFR), thyroid function (TSH), calcium. Side effects: tremor, GI upset, polyuria/polydipsia, weight gain, hypothyroidism. Meta-analytic evidence supports efficacy (NNT ~5), though many studies are older and small.

Atypical Antipsychotic Augmentation

Aripiprazole: most studied; FDA-approved for adjunctive treatment of MDD at 2-15 mg/day; partial D2 agonist minimizes metabolic risk; akathisia is the main limiting side effect. Quetiapine XR: FDA-approved for adjunctive MDD at 150-300 mg/day; significant sedation, weight gain, and metabolic effects; also has independent antidepressant properties via NET inhibition and 5-HT2A antagonism. Brexpiprazole: FDA-approved for adjunctive MDD at 1-3 mg/day; similar to aripiprazole but with lower D2 intrinsic activity, potentially less akathisia. Olanzapine/fluoxetine combination (OFC): FDA-approved for treatment-resistant depression; significant metabolic risk limits use. Cariprazine: FDA-approved adjunctive for MDD; partial D2/D3 agonist. Common concerns: metabolic syndrome, tardive dyskinesia risk with long-term use, unclear optimal duration of augmentation.

Thyroid Hormone Augmentation (T3)

Triiodothyronine (liothyronine / Cytomel) 25-50 mcg/day. May work even in euthyroid patients. Proposed mechanism: T3 enhances serotonergic neurotransmission in the brain; CNS hypothyroidism may exist despite normal serum levels. Better studied and preferred over T4 (levothyroxine) for augmentation. Generally well tolerated; monitor for tachycardia, tremor, insomnia. STAR*D Level 3: T3 augmentation equivalent to lithium with fewer side effects and dropouts.

Buspirone Augmentation

5-HT1A partial agonist. Modest evidence; STARD Level 2 showed similar efficacy to bupropion augmentation but less well tolerated. Dose: 15-60 mg/day in divided doses. Limited additional evidence outside of STARD.

Bupropion Augmentation

Adding bupropion (150-300 mg/day) to an SSRI/SNRI. Complements serotonergic agents by adding noradrenergic and dopaminergic activity. May mitigate SSRI-induced sexual dysfunction and fatigue. One of the most commonly used augmentation strategies in clinical practice. STAR*D Level 2: ~30% remission rate with SSRI + bupropion.

Stimulant and Modafinil Augmentation

Methylphenidate or modafinil added to antidepressant for fatigue, cognitive complaints, or residual symptoms. Limited controlled evidence; mostly open-label data. Useful in medically ill or palliative care populations. Risk of abuse/diversion with stimulants; modafinil generally preferred for off-label use.

Other Augmentation Approaches

Pindolol: 5-HT1A antagonist/beta-blocker; theoretically accelerates antidepressant response by blocking autoreceptors; mixed evidence. Omega-3 fatty acids (EPA): modest evidence from meta-analyses; EPA at 1-2 g/day may have anti-inflammatory antidepressant effects. L-methylfolate (Deplin): 15 mg/day; may be helpful in patients with MTHFR polymorphisms or folate deficiency; FDA-approved medical food. SAMe (S-adenosyl methionine): some RCT evidence supporting augmentation of SSRIs. Combination antidepressants: mirtazapine + venlafaxine ("California rocket fuel"), SSRI + mirtazapine; combining complementary mechanisms.

Switching Strategies

Within-Class vs. Between-Class Switching

Within-class switch (e.g., SSRI to another SSRI): ~25% remission rate; appropriate when first agent poorly tolerated. Between-class switch (e.g., SSRI to SNRI or bupropion): similar remission rates but may capture different mechanism non-responders. Cross-taper preferred to abrupt switch (except when switching to/from MAOIs, which require washout)

Switch vs. Augment: Decision Factors

Favor switching: non-response (no improvement), intolerable side effects, patient preference for monotherapy. Favor augmenting: partial response (some benefit from current agent), desire to preserve gains, target residual symptoms.

Summary: Comparison of Augmentation Strategies

Controversy: What Constitutes Adequate Evidence?

Many augmentation studies are industry-sponsored (atypical antipsychotics) with potential publication bias. Lithium augmentation has the longest history and most independent evidence but is often overlooked in favor of newer agents. Atypical antipsychotic augmentation carries significant long-term metabolic and neurological risks. The optimal duration of augmentation therapy is poorly studied. There is no strong head-to-head comparison between lithium and atypical antipsychotic augmentation.

<image> A stepped-care treatment algorithm based on the STAR*D trial design. Show four levels arranged as descending steps. Level 1: citalopram monotherapy (33% remission). Level 2: branches into "Switch" (sertraline, venlafaxine-XR, bupropion-SR, cognitive therapy) and "Augment" (bupropion, buspirone). Level 3: branches into "Switch" (nortriptyline, mirtazapine) and "Augment" (lithium, T3). Level 4: "Switch" (tranylcypromine or mirtazapine + venlafaxine). Show cumulative remission rate at each level. Clean flowchart with color-coded boxes for switch vs. augment paths. </image>

<image> A receptor-level diagram comparing the mechanisms of the major augmentation agents. Show four panels: (1) Lithium acting intracellularly on GSK-3beta and enhancing serotonergic transmission, (2) Aripiprazole as a partial D2 agonist at the dopaminergic synapse with stabilizing effect, (3) T3 thyroid hormone enhancing serotonergic neuron firing in the raphe nucleus, (4) Bupropion blocking NET and DAT at noradrenergic and dopaminergic synapses. Each panel should show the relevant synapse with labeled receptors and transporters. Medical illustration style. </image>

<image> An evidence summary infographic for augmentation strategies in TRD. Display a horizontal bar chart showing number-needed-to-treat (NNT) and relative risk of response for each strategy: lithium, aripiprazole, quetiapine, T3, bupropion, and brexpiprazole. Include icons indicating level of evidence (meta-analysis, RCT, open-label) and flags for key side effect concerns (metabolic risk, renal monitoring, akathisia). Clean data visualization style with a legend. </image>

Clinical Pearls

Always confirm true treatment resistance before pursuing augmentation: verify adequate dose, duration, and adherence for at least two prior trials. Lithium augmentation remains one of the most evidence-based strategies and is vastly underutilized; it also has unique anti-suicidal properties. T3 augmentation at 25-50 mcg/day is simple, well tolerated, and does not require the monitoring burden of lithium. Aripiprazole augmentation at 2-5 mg is effective and has fewer metabolic consequences than quetiapine or olanzapine, but monitor for akathisia. The "California rocket fuel" combination (venlafaxine + mirtazapine) is a potent strategy but carries significant sedation and weight gain risk. When augmenting with atypical antipsychotics, plan for a defined trial period (8-12 weeks) and reassess risk-benefit; avoid indefinite use without documented ongoing benefit. STAR*D teaches us that remission is achievable for most patients but often requires multiple sequential steps -- persistence and measurement-based care are key. Always screen for bipolarity before adding multiple serotonergic agents to a non-responding "depressed" patient.

References

• Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am J Psychiatry*. 2006;163(11):1905-1917.
• Trivedi MH, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STARD. Am J Psychiatry*. 2006;163(1):28-40.
• Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry. 2009;166(9):980-991.
• Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68(6):935-940.
• APA Practice Guidelines for the Treatment of Major Depressive Disorder. 3rd ed. 2010.
• Stahl SM. Stahl's Essential Psychopharmacology. 5th ed. 2021.

Read this lecture as Markdown